Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) Shares Outstanding (Weighted Average) (2020 - 2025)

Journey Medical (DERM) has disclosed Shares Outstanding (Weighted Average) for 5 consecutive years, with $23.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 15.05% year-over-year to $23.6 million, compared with a TTM value of $23.6 million through Sep 2025, up 15.05%, and an annual FY2024 reading of $20.4 million, up 12.06% over the prior year.
  • Shares Outstanding (Weighted Average) was $23.6 million for Q3 2025 at Journey Medical, up from $23.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $23.6 million in Q3 2025 and bottomed at $9.2 million in Q3 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $17.8 million, with a median of $18.1 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 90.65% in 2022, then rose 2.82% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $10.2 million in 2021, then surged by 72.05% to $17.5 million in 2022, then grew by 4.0% to $18.2 million in 2023, then rose by 12.06% to $20.4 million in 2024, then increased by 15.65% to $23.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for DERM at $23.6 million in Q3 2025, $23.3 million in Q2 2025, and $22.6 million in Q1 2025.